Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

EuroIntervention 2017;13:1168-1176 published online ahead of print August 2017. DOI: 10.4244/EIJ-D-17-00634

Paolo Zocca
Paolo Zocca1, MD; Liefke C. van der Heijden1, MD; Marlies M. Kok1, MD; Marije M. Löwik1, PhD; Marc Hartmann1, MD, PhD; Martin G. Stoel1, MD, PhD; J. (Hans) W. Louwerenburg1, MD; Frits H.A.F. de Man1, MD, PhD; Gerard C.M. Linssen2, MD, PhD; Iris L. Knottnerus3, MD, PhD; Carine J.M. Doggen4, PhD; K. Gert van Houwelingen1, MD; Clemens von Birgelen1,4*, MD, PhD
1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 2. Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, the Netherlands; 3. Department of Neurology, Medisch Spectrum Twente, Enschede,

Aims: Acute coronary syndrome (ACS) guidelines have been changed, favouring more potent antiplatelet drugs. We aimed to evaluate the safety and efficacy of a ticagrelor- instead of a clop

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

acute coronary syndromeadjunctive pharmacotherapyclinical researchnon-st-elevation acute coronary syndromest-elevation myocardial infarction
Read next article
Assessment of long-term mortality in patients with complex coronary artery disease undergoing percutaneous intervention: comparison of multiple anatomical and clinical prognostic risk scores

Latest news